You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Progenitor assay to screen proteins/molecules for treatment of type1 diabetes

    SBC: BETASTEM THERAPUETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human embryonic stem cells (HuES) have the potential to generate an unlimited source of beta/islet cells for transplantation, however the biologic factors required for this process have been difficult to ascertain partly due to the lack of stage specific in vitro cell assays. Recently, we have developed a murine in vitro pancreatic stem/progenitor colony assay ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. NOVEL THERAPEUTIC APPROACH TO PSORIASIS

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  4. NOVEL THERAPEUTIC APPROACH TO PSORIASIS

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. New Topical Therapies for Psoriasis

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we will ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. New Topical Therapies for Psoriasis

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we are in ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. MICRO ESOPHAGEAL RESPIRATORY CATHETER FOR SLEEP TESTING

    SBC: Bio Micronics, Inc.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  8. N/A

    SBC: Bio-Brite, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  9. Light Visor for Treating Jet Lag: Controlled Field Trial

    SBC: Bio-Brite, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Jet lag is a syndrome of behavioral, cognitive, and physical symptoms that result when travelers are exposed to a sudden shift of the day-night cycle. These symptoms impact on alertness and performance of airline and military personnel and the safety of the traveling public. They may also exacerbate medical and psychiatric illness, and frequent flyers may face ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  10. Light Visor for Treating Jet Lag: Controlled Field Trial

    SBC: Bio-Brite, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Jet lag is a syndrome of behavioral, cognitive, and physical symptoms that result when travelers are exposed to a sudden shift of the day-night cycle. These symptoms impact on alertness and performance of airline and military personnel and the safety of the traveling public. They may also exacerbate medical and psychiatric illness, and frequent flyers may face ...

    STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government